Optimizing mouse models for precision cancer prevention

Nature Reviews Cancer

Volumn 16, Issue 3, 2016, Pages 187-196

  Le Magnen, Clémentine ^a   Dutta, Aditya ^a   Abate Shen, Cory ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN;

ACCURACY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; DIET; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENETIC DRIFT; GENETIC HETEROGENEITY; GENETIC MANIPULATION; GENETIC VARIABILITY; GENETICALLY ENGINEERED MOUSE STRAIN; HEREDITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOUSE MODEL; NONHUMAN; PHENOTYPE; POPULATION GENETICS; PRECANCER; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SMOKING; SPECIES DIFFERENCE; SYSTEMIC THERAPY; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; MOUSE; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; PRECISION MEDICINE;

EID: 84959474882     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.1     Document Type: Review

References (134)

1. Welch, H. G., & Black, W. C. Overdiagnosis in cancer. J. Natl Cancer Inst. 102, 605-613 (2010
2. Lippman, S. M., et al. Cancer prevention and the American Society of Clinical Oncology. J. Clin. Oncol. 22, 3848-3851 (2004
3. Rebbeck, T. R. Precision prevention of cancer. Cancer Epidemiol. Biomarkers Prev. 23, 2713-2715 (2014
4. Meacham, C. E., & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337 (2013
5. Collins, F. S., & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015
6. Hawgood, S., Hook-Barnard, I. G., O'Brien, T. C., & Yamamoto, K. R. Precision medicine: beyond the inflection point. Sci. Transl Med. 7, 300ps31 (2015
7. Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15, 747-756 (2015
8. Narod, S. A. Breast cancer prevention in the era of precision medicine. J. Natl Cancer Inst. 107, djv078 (2015
9. Sieh, W., Rothstein, J. H., McGuire, V., & Whittemore, A. S. The role of genome sequencing in personalized breast cancer prevention. Cancer Epidemiol. Biomarkers Prev. 23, 2322-2327 (2014
10. Vaughan, T. L., & Fitzgerald, R. C. Precision prevention of oesophageal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 12, 243-248 (2015
11. William, W. N. Jr, et al. Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA Oncol., http://dx.doi.org/10.1001/jamaoncol.2015.4364 (2015
12. Rangarajan, A., & Weinberg, R. A. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3, 952-959 (2003
13. Van Dyke, T., & Jacks, T. Cancer modeling in the modern era: progress and challenges. Cell 108, 135-144 (2002
14. Hanahan, D., Wagner, E. F., & Palmiter, R. D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 21, 2258-2270 (2007
15. Green, J. E., & Hudson, T. The promise of genetically engineered mice for cancer prevention studies. Nat. Rev. Cancer 5, 184-198 (2005
16. Abate-Shen, C., et al. The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prevention Res. 1, 161-166 (2008
17. Grippo, P. J., & Tuveson, D. A. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prevention Res. 3, 1382-1387 (2010
18. Rosenberg, D. W., Giardina, C., & Tanaka, T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30, 183-196 (2009
19. Wang, Y., Rouggly, L., You, M., & Lubet, R. Animal models of lung cancer characterization and use for chemoprevention research. Prog. Mol. Biol. Transl Sci. 105, 211-226 (2012
20. Tentler, J. J., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012
21. Hidalgo, M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014
22. Frese, K. K., & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658 (2007
23. Sharpless, N. E., & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741-754 (2006
24. Heyer, J., Kwong, L. N., Lowe, S. W., & Chin, L. Non-germline genetically engineered mouse models for translational cancer research. Nat. Rev. Cancer 10, 470-480 (2010
25. Irshad, S., & Abate-Shen, C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev. 32, 109-122 (2013
26. Cohen, S. M. Urinary bladder carcinogenesis. Toxicol. Pathol. 26, 121-127 (1998
27. Kobayashi, T., Owczarek, T. B., McKiernan, J. M., & Abate-Shen, C. Modelling bladder cancer in mice: opportunities and challenges. Nat. Rev. Cancer 15, 42-54 (2015
28. Ittmann, M., et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 73, 2718-2736 (2013
29. Aytes, A., et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25, 638-651 (2014
30. Shibata, M., & Shen, M. M. The roots of cancer: stem cells and the basis for tumor heterogeneity. BioEssays 35, 253-260 (2013
31. Mestas, J., & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004
32. Zschaler, J., Schlorke, D., & Arnhold, J. Differences in innate immune response between man and mouse. Crit. Rev. Immunol. 34, 433-454 (2014
33. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012
34. Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786-798 (2012
35. Morse, H Origins of Inbred Mice (Academic Press, 1978
36. Hunter, K. W. Mouse models of cancer: does the strain matter? Nat. Rev. Cancer 12, 144-149 (2012
37. Churchill, G. A., et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36, 1133-1137 (2004
38. Threadgill, D. W., & Churchill, G. A. Ten years of the Collaborative Cross. Genetics 190, 291-294 (2012
39. Threadgill, D. W., Miller, D. R., Churchill, G. A., & de Villena, F. P. The collaborative cross: a recombinant inbred mouse population for the systems genetic era. ILAR J. 52, 24-31 (2011
40. Collaborative Cross Consortium. The genome architecture of the Collaborative Cross mouse genetic reference population. Genetics 190, 389-401 (2012
41. Threadgill, D. W., Hunter, K. W., & Williams, R. W. Genetic dissection of complex and quantitative traits: from fantasy to reality via a community effort. Mammal. Genome 13, 175-178 (2002
42. Roberts, A., Pardo-Manuel de Villena, F., Wang, W., McMillan, L., & Threadgill, D. W. The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. Mammal. Genome 18, 473-481 (2007
43. Rasmussen, A. L., et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346, 987-991 (2014
44. Phillippi, J., et al. Using the emerging Collaborative Cross to probe the immune system. Genes Immun. 15, 38-46 (2014
45. Ferguson, B., et al. Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression. Oncogene 34, 2879-2886 (2014
46. Patel, S. J., Molinolo, A. A., Gutkind, S., & Crawford, N. P. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS ONE 8, e61848 (2013
47. Churchill, G. A., Gatti, D. M., Munger, S. C., & Svenson, K. L. The Diversity Outbred mouse population. Mammal. Genome 23, 713-718 (2012
48. French, J. E., et al. Diversity Outbred mice identify population-based exposure thresholds and genetic factors that influence benzene-induced genotoxicity. Environ. Health Persp. 123, 237-245 (2015
49. Wang, Y., Tseng, J. C., Sun, Y., Beck, A. H., & Kung, A. L. Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. Cold Spring Harb. Protoc. 2015, 135-144 (2015
50. Mou, H., Kennedy, Z., Anderson, D G., Yin, H., & Xue, W. Precision cancer mouse models through genome editing with CRISPR Cas9. Genome Med. 7, 53 (2015
51. Sanchez-Rivera, F. J., & Jacks, T. Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 15, 387-395 (2015
52. Yuspa, S. H., & Poirier, M. C. Chemical carcinogenesis: from animal models to molecular models in one decade. Adv. Cancer Res. 50, 25-70 (1988
53. Balmain, A., & Yuspa, S. H. Milestones in skin carcinogenesis: the biology of multistage carcinogenesis. J. Invest. Dermatol. 134, E2-E7 (2014
54. Kemp, C. J. Animal models of chemical carcinogenesis: driving breakthroughs in cancer research for 100 years. Cold Spring Harb. Protoc. 2015, 865-874 (2015
55. Balmain, A., Brown, K., Akhurst, R. J., & Fee, F. M. Molecular analysis of chemical carcinogenesis in the skin. Bri. J. Cancer Suppl. 9, 72-75 (1988
56. Bain, J. A., & Rusch, H. P. Carcinogenesis with ultraviolet radiation of wave length 2, 800-3, 400 Å. Cancer Res. 3, 425-430 (1943
57. Fisher, M. S., & Kripke, M. L. Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science 216, 1133-1134 (1982
58. Kripke, M. L. The ABCs of sunscreen protection factors. J. Invest. Dermatol. 121, VII-VIII (2003
59. Walker, G. J., Soyer, H. P., Terzian, T., & Box, N. F. Modelling melanoma in mice. Pigment Cell. Melanoma Res. 24, 1158-1176 (2011
60. Hecht, S. S., et al. Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J. Natl Cancer Inst. 60, 819-824 (1978
61. Pfeifer, G. P., et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-Associated cancers. Oncogene 21, 7435-7451 (2002
62. Memmott, R. M., & Dennis, P. A. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin. Cancer Res. 16, 4-10 (2010
63. West, K. A., Linnoila, I. R., Belinsky, S. A., Harris, C. C., & Dennis, P. A. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3? kinase/Akt pathway in vitro and in vivo. Cancer Res. 64, 446-451 (2004
64. Wislez, M., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K ras. Cancer Res. 65, 3226-3235 (2005
65. Han, W., Gills, J. J., Memmott, R. M., Lam, S., & Dennis, P. A. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prevention Res. 2, 370-376 (2009
66. Lin, R. K., et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest. 120, 521-532 (2010
67. Kawabata, S., et al Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Rep. 7, 1824-1832 (2014
68. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01013831
69. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01294306
70. Kim, S. K., et al. Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. PLoS ONE 6, e26131 (2011
71. He, Z., Kosinska, W., Zhao, Z. L., Wu, X. R., & Guttenplan, J. B. Tissue-specific mutagenesis by N butyl N-(4 hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis. Mutat. Res. 742, 92-95 (2012
72. Nassar, D., Latil, M., Boeckx, B., Lambrechts, D., & Blanpain, C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat. Med. 21, 946-954 (2015
73. Westcott, P. M., et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489-492 (2015
74. Harvey, M., et al. Spontaneous and carcinogen-induced tumorigenesis in p53 deficient mice. Nat. Genet. 5, 225-229 (1993
75. Corpet, D. E., & Pierre, F. Point. From animal models to prevention of colon cancer. Systematic review of chemoprevention in Min mice and choice of the model system. Cancer Epidemiol. Biomarkers Prev. 12, 391-400 (2003
76. Ozaki, K., et al. High susceptibility of p53+/- knockout mice in N butyl N-(4 hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 58, 3806-3811 (1998
77. Van Batavia, J., et al. Bladder cancers arise from distinct urothelial sub-populations. Nat. Cell Biol. 16, 982-991 (2014
78. Philipp, J., Vo, K., Gurley, K. E., Seidel, K., & Kemp, C. J. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene 18, 4689-4698 (1999
79. Abate-Shen, C., & Pandolfi, P. P. Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials. Cold Spring Harb. Protoc. http://dx.doi.org/10.1101/pdb.top078774 (2013
80. Politi, K., & Pao, W. How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol. 29, 2273-2281 (2011
81. Olive, K. P., & Politi, K. Translational therapeutics in genetically engineered mouse models of cancer. Cold Spring Harb. Protoc. 2014, 131-143 (2014
82. Greenberg, N. M., et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92, 3439-3443 (1995
83. Shappell, S. B., et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64, 2270-2305 (2004
84. Gupta, S., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 64, 3334-3343 (2004
85. Narayanan, B. A., Narayanan, N. K., Pittman, B., & Reddy, B. S. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 10, 7727-7737 (2004
86. Wan, L., et al. Dietary tomato and lycopene impact androgen signaling-And carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis. Cancer Prevention Res. 7, 1228-1239 (2014
87. Ellwood-Yen, K., et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238 (2003
88. Iwata, T., et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE 5, e9427 (2010
89. Blando, J., et al. Dietary energy balance modulates prostate cancer progression in Hi Myc mice. Cancer Prevention Res. 4, 2002-2014 (2011
90. Oshima, M., et al. Suppression of intestinal polyposis in Apcδ716 knockout mice by inhibition of cyclooxygenase 2 (COX 2). Cell 87, 803-809 (1996
91. Steinbach, G., et al. The effect of celecoxib, a cyclooxygenase 2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000
92. Arber, N., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885-895 (2006
93. Solomon, S. D., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005
94. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205-213 (2003
95. Jordan, V. C. Tamoxifen as the first targeted long-Term adjuvant therapy for breast cancer. Endocr. Relat. Cancer 21, R235-R246 (2014
96. Jordan, V. C., & Koerner, S. Tamoxifen as an anti-Tumour agent: role of oestradiol and prolactin. J. Endocrinol. 68, 305-311 (1976
97. Ali, S., Buluwela, L., & Coombes, R. C. Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu. Rev. Med. 62, 217-232 (2011
98. Haslam, S. Z., Osuch, J. R., Raafat, A. M., & Hofseth, L. J. Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J. Mammary Gland Biol. Neoplasia 7, 93-105 (2002
99. Raafat, A. M., Hofseth, L. J., Li, S., Bennett, J. M., & Haslam, S. Z. A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: enhanced proliferative response to estrogen in late postmenopausal mice. Endocrinology 140, 2570-2580 (1999
100. Bosland, M. C. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog. Clin. Biol. Res. 394, 309-352 (1996
101. Bosland, M. C., et al. Multistage prostate carcinogenesis: the role of hormones. Princess Takamatsu Symp. 22, 109-123 (1991
102. Urayama, S. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J. Gastroenterol. 21, 1707-1717 (2015
103. Siegel, R., Ma, J., Zou, Z., & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014
104. Poruk, K. E., et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. Med. 13, 340-351 (2013
105. Westphalen, C. B., & Olive, K. P. Genetically engineered mouse models of pancreatic cancer. Cancer J. 18, 502-510 (2012
106. Mayers, J. R., et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20, 1193-1198 (2014
107. Hanash, S. M., & Taguchi, A. Mouse to human blood-based cancer biomarker discovery strategies. Cold Spring Harb. Protoc. 2014, 144-149 (2014
108. Kucherlapati, R. Genetically modified mouse models for biomarker discovery and preclinical drug testing. Clin. Cancer Res. 18, 625-630 (2012
109. Pitteri, S. J., et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE 4, e7916 (2009
110. Hung, K. E., et al. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prevention Res. 2, 224-233 (2009
111. Taguchi, A., et al. MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas. Cancer Prevention Res. 8, 1112-1119 (2015
112. Fijneman, R. J., et al. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin. Cancer Res. 18, 2613-2624 (2012
113. Taguchi, A., et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20, 289-299 (2011
114. Shaw, A. T., Kirsch, D. G., & Jacks, T. Future of early detection of lung cancer: the role of mouse models. Clin. Cancer Res. 11, 4999s-5003s (2005
115. Daskivich, T. J., et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 117, 2058-2066 (2011
116. Cooperberg, M. R., Carroll, P. R., & Klotz, L. Active surveillance for prostate cancer: progress and promise. J. Clin. Oncol. 29, 3669-3676 (2011
117. Irshad, S., et al. A molecular signature predictive of indolent prostate cancer. Sci. Transl Med. 5, 202ra122 (2013
118. Robles-Espinoza, C. D., & Adams, D. J. Cross-species analysis of mouse and human cancer genomes. Cold Spring Harb. Protoc. 2014, 350-358 (2014
119. Jacks, T. Tumor suppressor gene mutations in mice. Annu. Rev. Genet. 30, 603-636 (1996
120. Wang, J., & Abate-Shen, C. Analyses of tumor-suppressor genes in germline mouse models of cancer. Cold Spring Harb. Protoc. 2014, 807-812 (2014
121. Jacks, T., et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300 (1992
122. Jacks, T., et al. Tumor spectrum analysis in p53 mutant mice. Curr. Biol. 4, 1-7 (1994
123. Donehower, L. A., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992
124. Evers, B., & Jonkers, J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25, 5885-5897 (2006
125. Jonkers, J., & Berns, A. Conditional mouse models of sporadic cancer. Nat. Rev. Cancer 2, 251-265 (2002
126. Yeh, E. S., Vernon-Grey, A., Martin, H., & Chodosh, L. A. Tetracycline-regulated mouse models of cancer. Cold Spring Harb Protoc. http://dx.doi.org/10.1101/pdb.top069823 (2014
127. DuPage, M., Dooley, A. L., & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072 (2009
128. Branda, C. S., & Dymecki, S. M. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6, 7-28 (2004
129. Lyons, S. K., Patrick, P. S., & Brindle, K. M. Imaging mouse cancer models in vivo using reporter transgenes. Cold Spring Harb. Protoc. 2013, 685-699 (2013
130. Kretzschmar, K., & Watt, F. M. Lineage tracing. Cell 148, 33-45 (2012
131. Premsrirut, P. K., et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145, 145-158 (2011
132. Huijbers, I. J., Krimpenfort, P., Berns, A., & Jonkers, J. Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. BioEssays 33, 701-710 (2011
133. Wang, H., et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013
134. Shen, M. M., & Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000 (2010